Comparison · NCT00104676-sae
Arm I vs Arm II: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm I vs Arm II: serious adverse events. Trial comparisons, record NCT00104676-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00104676-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.378 | 0.288 | 0.476 | wilson | |
| Risk in group 2 | 0.552 | 0.457 | 0.644 | wilson | |
| Risk difference, group 1 minus group 2 | -0.175 | -0.303 | -0.0375 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.683 | 0.503 | 0.929 | log | |
| Odds ratio, group 1 over group 2 | 0.492 | 0.28 | 0.861 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Arm I than on Arm II | 5.72 | 3.3 | 26.7 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm I | Patients receive 4 courses of bleomycin, etoposide, and cisplatin (BEP).~bleomycin sulfate: At least one course administered~cisplatin: At least one course administered~etoposide: At least one course administered | 37 | 98 | EG000 |
| Group 2 | Arm II | Patients receive 1 course of bleomycin, etoposide, and cisplatin (BEP). Patients then receive dose-dense sequential combination chemotherapy comprising cisplatin, etoposide, bleomycin, paclitaxel, oxaliplatin, and ifosfamide.~bleomycin sulfate: At least one course administered~cisplatin: At least one course administered~etoposide: At least one course administered~ifosfamide: Given in a dose-dense sequential fashion~oxaliplatin: Given in a dose-dense sequential fashion~paclitaxel: Given in a dose-dense sequential fashion | 58 | 105 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors
- NCT number
- NCT00104676
- Phases
- PHASE3
- Conditions
- Extragonadal Germ Cell Tumor, Teratoma, Testicular Germ Cell Tumor
- Interventions
- bleomycin sulfate, cisplatin, etoposide, ifosfamide, oxaliplatin, paclitaxel
- Lead sponsor
- UNICANCER
- Results first posted
- 2021-06-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00104676?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00104676-sae